Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.

Bernstein DI, Pullum DA, Cardin RD, Bravo FJ, Dixon DA, Kousoulas KG.

Vaccine. 2019 Jan 3;37(1):61-68. doi: 10.1016/j.vaccine.2018.11.042. Epub 2018 Nov 22.

PMID:
30471955
2.

Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.

Stanfield BA, Rider PJF, Caskey J, Del Piero F, Kousoulas KG.

Vaccine. 2018 May 11;36(20):2842-2849. doi: 10.1016/j.vaccine.2018.03.075. Epub 2018 Apr 11.

PMID:
29655629
3.

Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.

J Infect Dis. 2009 Oct 1;200(7):1088-95. doi: 10.1086/605645.

4.

The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.

Bernstein DI, Farley N, Bravo FJ, Earwood J, McNeal M, Fairman J, Cardin R.

Vaccine. 2010 May 7;28(21):3748-53. doi: 10.1016/j.vaccine.2009.10.025. Epub 2009 Oct 24.

5.

Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.

Bernstein DI, Earwood JD, Bravo FJ, Cohen GH, Eisenberg RJ, Clark JR, Fairman J, Cardin RD.

Vaccine. 2011 Mar 3;29(11):2071-8. doi: 10.1016/j.vaccine.2011.01.005. Epub 2011 Jan 14.

6.

Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.

Visalli RJ, Natuk RJ, Kowalski J, Guo M, Blakeney S, Gangolli S, Cooper D.

Vaccine. 2014 Mar 10;32(12):1398-406. doi: 10.1016/j.vaccine.2013.10.079. Epub 2014 Jan 24.

PMID:
24462481
7.
8.

Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.

Bernard MC, Barban V, Pradezynski F, de Montfort A, Ryall R, Caillet C, Londono-Hayes P.

PLoS One. 2015 Apr 2;10(4):e0121518. doi: 10.1371/journal.pone.0121518. eCollection 2015.

9.

Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.

Bernstein DI, Cardin RD, Pullum DA, Bravo FJ, Kousoulas KG, Dixon DA.

PLoS One. 2019 Mar 27;14(3):e0213401. doi: 10.1371/journal.pone.0213401. eCollection 2019.

10.

Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.

Quenelle DC, Collins DJ, Rice TL, Prichard MN, Marciani DJ, Kern ER.

Antiviral Res. 2008 Nov;80(2):223-4. doi: 10.1016/j.antiviral.2008.05.011. Epub 2008 Jun 23.

11.

Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.

Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.

J Virol. 2017 Apr 13;91(9). pii: e02257-16. doi: 10.1128/JVI.02257-16. Print 2017 May 1.

12.

A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B.

PLoS One. 2011 Mar 11;6(3):e17748. doi: 10.1371/journal.pone.0017748.

13.

Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2012 Apr;86(8):4586-98. doi: 10.1128/JVI.07203-11. Epub 2012 Feb 8.

14.

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.

Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, Stanberry LR.

J Infect Dis. 2003 Feb 15;187(4):542-9. Epub 2003 Feb 7.

PMID:
12599070
15.
16.

Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.

Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, Baloglu S, Anderson SF, DiNapoli JM, Londoño-Hayes P, Parrington M, Almond J, Kleanthous H.

PLoS One. 2012;7(10):e46714. doi: 10.1371/journal.pone.0046714. Epub 2012 Oct 11.

17.

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH.

Vaccine. 2012 Oct 12;30(46):6541-6550. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.

18.

Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.

Hook LM, Cairns TM, Awasthi S, Brooks BD, Ditto NT, Eisenberg RJ, Cohen GH, Friedman HM.

PLoS Pathog. 2018 May 23;14(5):e1007095. doi: 10.1371/journal.ppat.1007095. eCollection 2018 May.

19.

Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.

Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, Kern ER, Kemble GM, Spaete RR.

Vaccine. 2005 Nov 16;23(46-47):5424-31. Epub 2005 Mar 19.

20.

Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.

J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13. Epub 2013 Nov 27.

Supplemental Content

Support Center